Gilead Sciences (GILD) Capital Expenditures Growth (3y) (2012 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Capex Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
-27.23% |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
51.53% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
6.72% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
14.83% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-0.53% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
27.44% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
2.39% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-27.39% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
7.67% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
2.39% |
| Dec 31, 2025 |
4.24% |
| Sep 30, 2025 |
-2.17% |
| Jun 30, 2025 |
-9.21% |
| Mar 31, 2025 |
-25.05% |
| Dec 31, 2024 |
-1.96% |
| Sep 30, 2024 |
0.48% |
| Jun 30, 2024 |
2.99% |
| Mar 31, 2024 |
-13.99% |
| Dec 31, 2023 |
5.91% |
| Sep 30, 2023 |
-7.67% |
| Jun 30, 2023 |
-0.94% |
| Mar 31, 2023 |
-13.94% |
| Dec 31, 2022 |
-3.75% |
| Sep 30, 2022 |
-7.75% |
| Jun 30, 2022 |
-8.23% |
| Mar 31, 2022 |
1.39% |
| Dec 31, 2021 |
-14.32% |
| Sep 30, 2021 |
-5.93% |
| Jun 30, 2021 |
-26.28% |
| Mar 31, 2021 |
-8.02% |
| Dec 31, 2020 |
-6.30% |
| Sep 30, 2020 |
6.31% |
| Jun 30, 2020 |
5.15% |
| Mar 31, 2020 |
13.16% |
| Dec 31, 2019 |
6.30% |
| Sep 30, 2019 |
0.34% |
| Jun 30, 2019 |
-3.21% |
| Mar 31, 2019 |
10.22% |
| Dec 31, 2018 |
14.32% |
| Sep 30, 2018 |
-16.42% |
| Jun 30, 2018 |
20.20% |
| Mar 31, 2018 |
19.57% |
| Dec 31, 2017 |
9.62% |
| Sep 30, 2017 |
-1.50% |
| Jun 30, 2017 |
10.57% |
| Mar 31, 2017 |
-10.39% |
| Dec 31, 2016 |
35.00% |
| Sep 30, 2016 |
74.63% |
| Jun 30, 2016 |
65.17% |
| Mar 31, 2016 |
65.77% |
| Dec 31, 2015 |
-14.95% |
| Sep 30, 2015 |
62.55% |
| Jun 30, 2015 |
65.99% |
| Mar 31, 2015 |
74.84% |
| Dec 31, 2014 |
85.63% |
| Sep 30, 2014 |
28.06% |
| Jun 30, 2014 |
50.61% |
| Mar 31, 2014 |
122.59% |
| Dec 31, 2013 |
43.26% |
| Sep 30, 2013 |
50.97% |
| Jun 30, 2013 |
41.29% |
| Mar 31, 2013 |
49.34% |
| Dec 31, 2012 |
115.43% |
| Sep 30, 2012 |
54.30% |
| Jun 30, 2012 |
21.45% |
| Mar 31, 2012 |
-47.90% |